« Return to News | CROs/Service Providers

Encorium Doubles Loss in Q2, Continues Effort to Sell European Subsidiary

Tuesday, August 25, 2009 07:08 AM

Encorium’s losses continued to grow in the second quarter, increasing $604,000  to $1.3 million or $(0.06) per diluted share, compared with a net loss of $665,000, or $(0.03) per diluted share for the same period last year.

Net revenue for the quarter also plunged to $4.5 million, a 23.37% drop compared with last year’s quarter. Year-to-date revenues were $9.02 million, down from $11.32 million in 2008.

The Wayne, Pa.-based contract research organization (CRO) entered into a non-binding letter of intent to sell its European subsidiary, Encorium Oy, in May, but that sale has yet to materialize.  As part of the company’s financial results released Monday night, Encorium said it does not expect this transaction to close until the fourth quarter. In the event the sale does not go through, the CRO said it will seek strategic alternatives, including an attempt to secure additional financing.

“If we are unable to secure additional financing on terms acceptable to us and on a timely basis, we may significantly reduce our operating costs, which may include the cessation of operations in some countries or seek stockholder approval to liquidate and dissolve. Any decision to liquidate and dissolve the company may occur at any point during or before the first quarter of 2010. It is unclear whether there would be funds available for distribution to our stockholders in these instances,” Encorium said in a press release.

Encorium completed the sale of its U.S. operations to Pierrel Research USA last month.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.